导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.17% | 1798/4773 |
| 近一周 | -1.28% | 2337/5467 |
| 近一月 | -3.16% | 1154/5421 |
| 近一季 | -4.77% | 1682/5238 |
| 近半年 | -3.55% | 2739/4931 |
| 近一年 | 4.77% | 1619/4400 |
| 近两年 | 32.53% | 2168/2954 |
| 近三年 | 20.60% | 1444/2253 |
| 成立以来 | 71.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.32% 1575/4961 |
7.82% 2660/5312 |
- - |
- - |
| 2025 | 6.16% 2973/4813 |
-5.04% 3250/3635 |
1.17% 2436/4076 |
10.37% 3300/4524 |
0.12% 2202/4813 |
| 2024 | 17.49% 684/3463 |
5.12% 402/2808 |
2.31% 359/3014 |
9.69% 2676/3129 |
-0.40% 1407/3463 |
| 2023 | 2.56% 311/2656 |
13.08% 279/2280 |
-0.37% 380/2385 |
-4.80% 1225/2515 |
-4.38% 996/2655 |
| 2022 | -15.06% 407/2207 |
-12.27% 597/1919 |
3.39% 1159/2016 |
-10.18% 360/2113 |
4.27% 568/2208 |
| 2021 | 19.32% 195/1822 |
0.41% 297/1255 |
5.00% 829/1330 |
10.33% 125/1466 |
2.57% 562/1822 |
| 2020 | 15.81% 779/1250 |
-10.54% 790/1028 |
4.44% 907/1067 |
10.28% 566/1164 |
12.39% 471/1184 |
| 2019 | 9.02% 734/1092 |
15.42% 685/754 |
-6.48% 510/804 |
-1.56% 665/850 |
2.59% 861/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银华中证央企结构调整ETF VS. 长安沪深300非周期A(740101) |